PCVX in the 13F filings
Vaxcyte Inc · CUSIP 92243G108
- Quarter end
- 30 Sep 2024
- the date the book describes
- Filed
- 5 Nov 2026
- latest of these filings; the earliest 13 Nov 2024
- Managers listing it
- 12
- at least, of 95 tracked, among listed positions
- Comparable managers
- 94
- filed both Q2 2024 and Q3 2024; 9 listed it in both
- Shares listed
- 45,020,037
- combined, among listed positions
- Reported value
- $5.1bn
- combined, at the quarter end
Among the 94 comparable managers: 8 buyers (opened or added shares) and 4 sellers (trimmed or exited), at least, among listed positions. Their net change in shares is not known from listed positions, because at least one of them lists it in only one of the two quarters.
Managers listing PCVX in Q3 2024
12 of 12 holders
Largest increases and reductions, by shares
Increases
- Janus Henderson Group Ltdexisting position · 10,921,896 shares now+2,052,989
- T. Rowe Price Associates Incexisting position · 4,466,137 shares now+1,292,970
- Capital Research Global Investorsexisting position · 4,898,221 shares now+764,677
- Woodline Partners LPexisting position · 1,103,945 shares now+397,042
- Point72 Asset Management LPnew position · 359,796 shares now+359,796
Reductions
- Fidelity (FMR LLC)existing position · 15,800,667 shares now-366,673
- Farallon Capital Management LLCexisting position · 28,000 shares now-262,000
- AllianceBernstein LPexisting position · 1,645,914 shares now-88,907
- Wellington Management Group LLPexisting position · 4,513,756 shares now-79,310
New positions and exits
Exited (0)
No exit shown by a manager’s own filing.
Ownership over time
Tracked managers listing it, at least.
| Quarter | Holders | Reported value | Buyers | Sellers |
|---|---|---|---|---|
| Q2 2020 | 2 | $141m | n.a. | n.a. |
| Q3 2020 | 2 | $515m | n.a. | n.a. |
| Q4 2020 | 1 | $108m | n.a. | n.a. |
| Q1 2021 | 1 | $84m | n.a. | n.a. |
| Q2 2021 | 1 | $93m | n.a. | n.a. |
| Q3 2021 | 1 | $104m | n.a. | n.a. |
| Q4 2021 | 2 | $103m | n.a. | n.a. |
| Q1 2022 | 2 | $106m | n.a. | n.a. |
| Q2 2022 | 4 | $107m | n.a. | n.a. |
| Q3 2022 | 5 | $140m | n.a. | n.a. |
| Q4 2022 | 12 | $1.2bn | n.a. | n.a. |
| Q1 2023 | 8 | $978m | n.a. | n.a. |
| Q2 2023 | 8 | $1.6bn | n.a. | n.a. |
| Q3 2023 | 9 | $1.8bn | n.a. | n.a. |
| Q4 2023 | 9 | $2.1bn | 5 | 4 |
| Q1 2024 | 9 | $2.7bn | 8 | 1 |
| Q2 2024 | 10 | $3.1bn | 4 | 6 |
| Q3 2024 | 12 | $5.1bn | 8 | 4 |
| Q4 2024 | 11 | $3.6bn | 6 | 6 |
| Q1 2025 | 6 | $1.8bn | 3 | 3 |
| Q2 2025 | 7 | $969m | 5 | 2 |
| Q3 2025 | 9 | $940m | 5 | 5 |
| Q4 2025 | 9 | $1.8bn | 13 | 18 |
| Q1 2026 | 12 | $2.7bn | 18 | 13 |
| Q2 2026 | 8 | $2.9bn | 13 | 17 |
Compare with…
Holders over time, buyers and sellers, and the managers holding both, side by side for up to four stocks.
PCVX and GILD →PCVX and AMGN →PCVX and ARGX →Choose a stock to compare with PCVX →
How much of the picture this is
A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. It shows no shorts, cash, bonds or performance, and it is never today’s portfolio. Large books are listed to their largest positions, so a manager missing from this table may still hold a small position below that line. These are 95 tracked managers, not the institutional market.
Which funds own PCVX, latest filings →Back to the 13F Explorer →